BMS Highlights Pooled Interim Data from the P-III (EMERGENT) Program of KarXT for Schizophrenia at the SIRS 2024
Shots:
- The presentations were titled as, “Long-Term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia” & “Long-Term Metabolic Outcomes Associated With KarXT (Xanomeline and Trospium): Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5”
- The P-III (EMERGENT-4 & EMERGENT-5) studies assessed KarXT’s safety, tolerability & efficacy for schizophrenia. Interim analysis, as of Aug 2023, had 718 patients receiving at least 1 dose & 134 patients completing 1yr. of treatment
- The data showed overall wt. reduction in 65% of patients with 18% & 4% achieving decreases & increases in wt. (≥7% change), respectively. Patients (BMI>30kg/m^2) completing 52wks. of treatment had an avg. wt. reduction of 2.6kg with a mean wt. reduction of 4.1kg
Ref: BMS | Image: BMS
Related News:- BMS’ Reblozyl Gains CHMP’s Positive Opinion to Treat Transfusion-Dependent Anemia Due to Myelodysplastic Syndrome (MDS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
